Caris Life Sciences Finalizes Achieve 1 Study; Results Demonstrate The Superiority Of Whole Genome Sequencing Compared To Methylation-Based Approaches

Caris Life Sciences (NASDAQ: CAI) has finalized the results of its Achieve 1 Study, which demonstrates the superiority of its Caris Detect multi-cancer early detection test over methylation-based approaches. The study involved 3,014 subjects and aimed to assess the diagnostic accuracy of Caris Detect in identifying early-stage cancers through peripheral blood sampling. This milestone supports Caris' objective of enhancing early cancer detection using its extensive molecular profiling data, which has processed over 1 million cases.